Mechanism of action of Duvelisib (Copiktra); oral delta and gamma PI3K inhibitor. This dual isoform blockage inhibits cell signaling within malignant B cells and between malignant cells and the tumor microenvironment (TME). Blocking PI3K delta pathways from activated BCR, cytokine, and CD40 receptors affects the growth and survival of malignant B cells. Blocking PI3K gamma affects the recruitment and differentiation of the CD4+ T cells and Tumor Associated Myeloid cells that support the growth and survival of malignant B cells.